Skip to main content

Mesoblast Ltd

MESO
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001345099

No open-market purchases or sales by Mesoblast Ltd insiders were filed in the last 90 days; 72 institutions reported holding it in 13F filings for Q2 2026, worth $53.3M in total; no superinvestor holds it.

Other share classesMEOBF

Q2 2022 vs. Q1 2022

How the institutions holding Mesoblast Ltd changed between Q1 2022 and Q2 2022.

All holders in Q2 2022All holders in Q1 2022

13F holders of MESO: Q1 2022 compared with Q2 2022
MeasureQ1 2022Of which not filed for Q2 2022Q2 2022Change
Holders37133−3
Shares3.17M15.2K3.31M+148.7K (+4.7%)
Value$13.1M$64.0K$7.06M−$5.96M (−45.8%)

1 institution that held it in Q1 2022 haven't filed for Q2 2022 yet. Not filing isn't selling, so the changes leave them out.

New holders (4)

Institutions that held Mesoblast Ltd at the end of Q2 2022 but not at the end of Q1 2022.

Institutions new to MESO in Q2 2022
InstitutionSharesValue% of portfolio
Simplex Trading, LLC15,124$33.0K0.00%
Merit Financial Group, LLC12,122$27.0K0.00%
Group One Trading, L.P.10,450$23.0K0.00%
Covington Capital Management500$1.00K0.00%

Sold out (7)

Institutions that held Mesoblast Ltd at the end of Q1 2022 and filed for Q2 2022 without it.

Institutions that sold out of MESO in Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Cambridge Investment Research Advisors, Inc.11,000$46.0K
Cutler Group LP1,536$6.00K
Signaturefd, LLC733$3.00K
Cypress Capital Management LLC (WY)750$3.00K
Parallel Advisors, LLC167$1.00K
Financial Management Professionals, Inc.57$0
Investors Research Corp1$0

Not filed for Q2 2022 yet (1)

Institutions that held Mesoblast Ltd at the end of Q1 2022 and haven't filed a 13F for Q2 2022. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding MESO in Q1 2022 that haven't filed for Q2 2022
InstitutionShares, Q1 2022Value, Q1 2022
Susquehanna Fundamental Investments, LLC15,181$64.0K